Merrimack Pharmaceuticals (Nasdaq: MACK) has extended its Section 382 net operating loss rights plan until December 2, 2025, to preserve its valuable net operating loss carryforwards and tax attributes. This plan aims to mitigate corporate tax payments associated with potential milestone payments. CEO Gary Crocker emphasized that using these NOLs could enhance future shareholder distributions. However, the extension requires shareholder approval at the upcoming 2023 annual meeting.
Merrimack Pharmaceuticals (MACK) announced that Ipsen reported positive results from the Phase III NAPOLI 3 trial of Onivyde, showing a significant improvement in overall survival for metastatic pancreatic ductal adenocarcinoma patients. Ipsen plans to file a supplemental New Drug Application with the FDA, potentially triggering milestone payments for Merrimack.
CEO Gary Crocker expressed optimism about the results, highlighting potential future payments up to $450 million depending on regulatory approval.
Merrimack Pharmaceuticals (MACK) reported a net loss of $442 thousand for Q3 2022, down from $525 thousand in Q3 2021. General and administrative expenses decreased to $504 thousand from $619 thousand year-over-year. Cash and equivalents stood at $13.1 million, a decline from $14.6 million. Updates on clinical programs include Ipsen’s Onivyde study results and Elevation Oncology’s upcoming phase 2 data expected in 2024.
Merrimack Pharmaceuticals reported a net loss of $478,000 for Q2 2022, or $0.04 per share, an improvement from a loss of $759,000 or $0.06 per share in Q2 2021. Operating expenses decreased significantly to $486,000 from $778,000 year-over-year. As of June 30, 2022, the company had $13.4 million in cash and equivalents, down from $14.2 million at the end of 2021. Merrimack continues to rely on milestone payments from Ipsen and Elevation Oncology, with potential payments totaling $450 million and $54.5 million respectively.
Merrimack Pharmaceuticals (NASDAQ: MACK) reported that Ipsen's Phase 3 trial of Onivyde for small cell lung cancer did not meet its primary endpoint of overall survival. However, Onivyde showed a significant improvement in the secondary objective response rate. The safety profile remained unchanged, and no new safety concerns were identified. Ipsen will conduct further analysis before determining the next steps. Merrimack is entitled to potential milestone payments from Ipsen linked to Onivyde's future approvals.
Merrimack Pharmaceuticals (MACK) reported its first quarter 2022 results with a net loss of $132,000, or $0.01 per share, improved from a $696,000 loss in Q1 2021. The company gained $445,000 from the sale of preclinical assets. Operating expenses were reduced to $577,000 from $746,000 year-over-year. Merrimack maintained cash reserves at $14.3 million as of March 31, 2022, slightly up from $14.2 million at the end of 2021. The company is positioned to receive milestone payments from Ipsen and Elevation Oncology.
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) reported a net loss of $2.5 million for 2021, an improvement from a $3.0 million loss in 2020. General administrative expenses declined to $2.6 million. The company maintained cash reserves at $14.2 million, slightly up from $14.0 million in 2020. Merrimack is poised to receive future milestone payments, up to $450 million from Ipsen and $54.5 million from Elevation Oncology, contingent on clinical trial successes expected in 2022 and 2023.
Merrimack Pharmaceuticals reported a net loss of $0.5 million for Q3 2021, an improvement from $1.0 million the previous year. Their cash position increased to $14.6 million from $14.0 million at year-end 2020, aided by operational cost reductions and receipt of a tax refund. Updates from partners Ipsen and Elevation Oncology indicate ongoing progress in clinical trials, including data expected from key trials in 2022 and 2023 that could trigger milestone payments up to $450 million.
Merrimack Pharmaceuticals (Nasdaq:MACK) reported a net loss of $0.8 million for Q2 2021, improved from a $1.2 million loss in Q2 2020. General and administrative expenses have decreased to $0.8 million from $1.2 million year-over-year. As of June 30, 2021, cash and equivalents rose to $14.9 million, up from $14.0 million at the end of 2020, primarily due to a federal tax refund. Progress continues on clinical programs with Ipsen Pharmaceuticals and Elevation Oncology that could lead to future milestone payments.
Merrimack Pharmaceuticals (MACK) reported a net loss of $3.0 million for the fiscal year 2020, significantly improved from a net loss of $17.3 million in 2019. The company saw a reduction in general and administrative expenses, totaling $5.0 million for the year, down from $16.2 million the previous year. As of December 31, 2020, Merrimack held $14.0 million in cash and equivalents, down from $16.6 million in 2019. The company remains focused on potential milestone payments from Ipsen Pharmaceuticals and Elevation Oncology, with ongoing clinical developments that could yield future income.